ATE474587T1 - Inhibitoren des hepatitis-c-virus - Google Patents

Inhibitoren des hepatitis-c-virus

Info

Publication number
ATE474587T1
ATE474587T1 AT05814026T AT05814026T ATE474587T1 AT E474587 T1 ATE474587 T1 AT E474587T1 AT 05814026 T AT05814026 T AT 05814026T AT 05814026 T AT05814026 T AT 05814026T AT E474587 T1 ATE474587 T1 AT E474587T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
present
methods
virus inhibitors
Prior art date
Application number
AT05814026T
Other languages
English (en)
Inventor
Robert Garry
Jane A Mckeating
Original Assignee
Univ Tulane
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Univ Rockefeller filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE474587T1 publication Critical patent/ATE474587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT05814026T 2004-09-29 2005-09-26 Inhibitoren des hepatitis-c-virus ATE474587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61428004P 2004-09-29 2004-09-29
PCT/US2005/034777 WO2006039326A2 (en) 2004-09-29 2005-09-26 Inhibitors of hepatitits c virus

Publications (1)

Publication Number Publication Date
ATE474587T1 true ATE474587T1 (de) 2010-08-15

Family

ID=36143015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814026T ATE474587T1 (de) 2004-09-29 2005-09-26 Inhibitoren des hepatitis-c-virus

Country Status (11)

Country Link
US (2) US7381705B2 (de)
EP (1) EP1797112B1 (de)
JP (1) JP4980915B2 (de)
AT (1) ATE474587T1 (de)
AU (1) AU2005292135B2 (de)
CA (1) CA2582095A1 (de)
DE (1) DE602005022463D1 (de)
ES (1) ES2349153T3 (de)
PL (1) PL1797112T3 (de)
PT (1) PT1797112E (de)
WO (1) WO2006039326A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510122A (ja) * 2005-09-29 2009-03-12 ザ スクリプス リサーチ インスティテュート ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
WO2009030872A1 (de) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Vorrichtung zum festlegen einer gliedmasse
CA2710406A1 (en) * 2007-09-11 2009-04-09 Dorian Bevec Use of a peptide as a therapeutic agent
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
DK2763696T3 (en) 2011-10-07 2018-10-15 Isd Immunotech Aps Identification of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
CN104324361A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte2序列及应用
CN109232721B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段418-429及其用途
CN114630698A (zh) * 2019-07-26 2022-06-14 斯克里普斯研究学院 经改造hcv e2免疫原和相关疫苗组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
DE69432475T2 (de) * 1993-11-04 2004-03-04 Innogenetics N.V. Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
WO1998039487A1 (en) * 1997-03-05 1998-09-11 Ribogene, Inc. Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
US6153421A (en) 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6127166A (en) * 1997-11-03 2000-10-03 Bayley; Hagan Molluscan ligament polypeptides and genes encoding them
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
EP1178116A1 (de) * 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nukleische Saüre und aus einem pathogenischen Stamm des Hepatitis C Viruses selektierte Polypeptide und deren Verwendungenthereof
EP2332574A1 (de) * 2000-08-17 2011-06-15 Tripep Ab HCV NS3/4A Sequenzen
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP5250179B2 (ja) 2002-11-08 2013-07-31 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド フラビウイルス融合インヒビター
JP2007537975A (ja) * 2003-06-10 2007-12-27 ザ　ユニバーシティー　オブ　メルボルン 免疫調節性組成物、それらについての使用方法およびそれらの製造のための方法

Also Published As

Publication number Publication date
ES2349153T3 (es) 2010-12-28
DE602005022463D1 (de) 2010-09-02
US20080241156A1 (en) 2008-10-02
US20060069027A1 (en) 2006-03-30
WO2006039326A2 (en) 2006-04-13
CA2582095A1 (en) 2006-04-13
US7381705B2 (en) 2008-06-03
AU2005292135A1 (en) 2006-04-13
AU2005292135B2 (en) 2011-09-29
JP2008514717A (ja) 2008-05-08
JP4980915B2 (ja) 2012-07-18
PT1797112E (pt) 2010-10-25
WO2006039326A3 (en) 2007-05-10
EP1797112A2 (de) 2007-06-20
EP1797112A4 (de) 2009-04-01
PL1797112T3 (pl) 2011-04-29
EP1797112B1 (de) 2010-07-21

Similar Documents

Publication Publication Date Title
ATE474587T1 (de) Inhibitoren des hepatitis-c-virus
EA200700243A1 (ru) Способы лечения гепатита с
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
NO20044897L (no) Hepatitt C virus inhibitorer
EA200801050A1 (ru) Соединения и способы ингибирования репликации вирусного гепатита с
ATE541844T1 (de) Antivirale verbindungen
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
DE602006015861D1 (de) Antivirale verbindungen
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
EA200700338A1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
EA201171152A1 (ru) Ингибиторы вируса гепатита c
CO6450600A2 (es) Inhibidores de anillo fusionado de hepatitis c
NZ593808A (en) Inhibitors of hcv ns5a
EA201170353A1 (ru) Антитела против гепатита с и их применение
NO20055057L (no) Farmasoytiske blandinger for hepatitt C virale-priteaseinhibitorer
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
WO2008017692A3 (en) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
ATE391721T1 (de) Modifizierte hiv-1-peptide und ihre verwendung beim nachweisen von anti-hiv-antikörpern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties